Ravi Madan
@ravimadan.bsky.social
Clinical researcher focused on #ProstateCancer, early recurrence (#BCR/PSMA+ BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute #Medsky
Clinical and #Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive #ProstateCancer @EUplatinum
#PSMA
www.sciencedirect.com/science/arti...
#PSMA
www.sciencedirect.com/science/arti...
November 11, 2025 at 12:56 PM
Clinical and #Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive #ProstateCancer @EUplatinum
#PSMA
www.sciencedirect.com/science/arti...
#PSMA
www.sciencedirect.com/science/arti...
More information on the clinical trial & how to refer patients
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
Study link
www.clinicaltrials.gov/study/NCT055...
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
Study link
www.clinicaltrials.gov/study/NCT055...
ClinicalTrials.gov
www.clinicaltrials.gov
October 18, 2025 at 9:44 AM
More information on the clinical trial & how to refer patients
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
Study link
www.clinicaltrials.gov/study/NCT055...
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
Study link
www.clinicaltrials.gov/study/NCT055...
More information on the clinical trial & how to refer patients
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
www.clinicaltrials.gov/study/NCT055...
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
www.clinicaltrials.gov/study/NCT055...
ClinicalTrials.gov
www.clinicaltrials.gov
October 18, 2025 at 9:41 AM
More information on the clinical trial & how to refer patients
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
www.clinicaltrials.gov/study/NCT055...
#ESMO25
#BCR #ProstateCancer
Much more data to follow from this trial helping define who needs treatment in #PSMA+ BCR & who does NOT (which is most pts as the data demonstrate)
www.clinicaltrials.gov/study/NCT055...
One that allows questioning of the data with the intent of understanding it better as opposed to “amplifying” the original message.
September 26, 2025 at 2:53 PM
One that allows questioning of the data with the intent of understanding it better as opposed to “amplifying” the original message.
In short. Yes. I do think #serosal lesions on #PSMA in #BCR do not present an urgent clinical threat. We are evaluating this further on our ongoing study of Prospective PSMAs in BCR #ProstateCancer
www.clinicaltrials.gov/study/NCT055...
www.clinicaltrials.gov/study/NCT055...
ClinicalTrials.gov
www.clinicaltrials.gov
September 18, 2025 at 4:11 PM
In short. Yes. I do think #serosal lesions on #PSMA in #BCR do not present an urgent clinical threat. We are evaluating this further on our ongoing study of Prospective PSMAs in BCR #ProstateCancer
www.clinicaltrials.gov/study/NCT055...
www.clinicaltrials.gov/study/NCT055...
More examples of indolent serosal findings emerging from our ongoing #PSMA imaging study in #BCR #ProstateCancer @theNCI which has enrolled over 140 patients and continues to enroll.
See link for more details
www.clinicaltrials.gov/study/NCT055...
See link for more details
www.clinicaltrials.gov/study/NCT055...
ClinicalTrials.gov
www.clinicaltrials.gov
August 21, 2025 at 12:28 PM
More examples of indolent serosal findings emerging from our ongoing #PSMA imaging study in #BCR #ProstateCancer @theNCI which has enrolled over 140 patients and continues to enroll.
See link for more details
www.clinicaltrials.gov/study/NCT055...
See link for more details
www.clinicaltrials.gov/study/NCT055...
Not the first example of indolent serosal findings on #PSMA in #ProstateCancer
This pt with findings in 2018
tinyurl.com/29tpcddy
@ascocancer.bsky.social
This patient with serosal findings on the liver remains without parenchymal Mets in 2025. Went most of the 7 years without treatment.
This pt with findings in 2018
tinyurl.com/29tpcddy
@ascocancer.bsky.social
This patient with serosal findings on the liver remains without parenchymal Mets in 2025. Went most of the 7 years without treatment.
August 21, 2025 at 12:27 PM
Not the first example of indolent serosal findings on #PSMA in #ProstateCancer
This pt with findings in 2018
tinyurl.com/29tpcddy
@ascocancer.bsky.social
This patient with serosal findings on the liver remains without parenchymal Mets in 2025. Went most of the 7 years without treatment.
This pt with findings in 2018
tinyurl.com/29tpcddy
@ascocancer.bsky.social
This patient with serosal findings on the liver remains without parenchymal Mets in 2025. Went most of the 7 years without treatment.
Agree. Important point. There has always been a reluctance to use chemo in #ProstateCancer
It underpins the lack of 2nd line treatments s/p ARPI data from 2015-2020ish
Could argue it’s efficacy after arpi is unstudied but not a reason not to use
Every treatment has its place
It underpins the lack of 2nd line treatments s/p ARPI data from 2015-2020ish
Could argue it’s efficacy after arpi is unstudied but not a reason not to use
Every treatment has its place
July 27, 2025 at 1:51 PM
Agree. Important point. There has always been a reluctance to use chemo in #ProstateCancer
It underpins the lack of 2nd line treatments s/p ARPI data from 2015-2020ish
Could argue it’s efficacy after arpi is unstudied but not a reason not to use
Every treatment has its place
It underpins the lack of 2nd line treatments s/p ARPI data from 2015-2020ish
Could argue it’s efficacy after arpi is unstudied but not a reason not to use
Every treatment has its place
Agree @profiand.bsky.social
#ProatateCancer
Would also suggest that PFS of 2 agents vs 1 without adequate crossover should always be superior and such a trial answers few ?s except toxicity which will undoubtedly be “manageable”
www.nature.com/articles/s41...
#ProatateCancer
Would also suggest that PFS of 2 agents vs 1 without adequate crossover should always be superior and such a trial answers few ?s except toxicity which will undoubtedly be “manageable”
www.nature.com/articles/s41...
Progression-free survival end points in prostate cancer: are we truly making progress - Nature Reviews Urology
Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic devel...
www.nature.com
July 27, 2025 at 1:50 PM
Agree @profiand.bsky.social
#ProatateCancer
Would also suggest that PFS of 2 agents vs 1 without adequate crossover should always be superior and such a trial answers few ?s except toxicity which will undoubtedly be “manageable”
www.nature.com/articles/s41...
#ProatateCancer
Would also suggest that PFS of 2 agents vs 1 without adequate crossover should always be superior and such a trial answers few ?s except toxicity which will undoubtedly be “manageable”
www.nature.com/articles/s41...